Shares in focus: Tobacco stocks have life in them yet

News of the death of big tobacco firms has been exaggerated, says Phil Oakley.

Up until quite recently, shares in British American Tobacco (BATS) have proved to be a very good long-term investment. BATS has been able to grow nicely, despite governments around the world trying very hard to discourage people from smoking.

A strategy based around premium cigarette brands, buying other companies and cutting lots of costs turbocharged profits, dividends and the share price over the last decade.

Now life seems to be getting a little tougher for BATS and the tobacco industry in general. Governments are still looking for their pound of flesh, while changes in smoking habits – such as e-cigarettes – have created fresh threats to their business models.

Investors have become more nervous about the company’s prospects and BATS’s shares have gone nowhere for the past year.

Calling the death of the big tobacco companies is nothing new. But could the doomsters be right this time? Or is BATS an unloved bargain?

The rise of the e-cigarette

Is BATS running out of puff? That seems to be the main concern that investors have at the moment. In the past it has been able to shake off the threats of higher taxes, a growing illegal trade in cigarettes and increased regulations on advertising.

Now some analysts are worried that the introduction of e-cigarettes will decimate the tobacco industry, particularly in Western markets. While the market for e-cigarettes is at a very early stage and makes up less than 1% of the total number of cigarettes smoked worldwide, it’s growing quickly.

E-cigarettes don’t contain tobacco, but are based on inhaling nicotine vapours (instead of smoking, you ‘vape’). They are not subject to tobacco duty and are therefore much cheaper than traditional cigarettes and are also marketed as a healthier alternative.

How much cheaper e-cigarettes are is a matter of debate, as it depends on how people smoke (how many puffs they get out of each cigarette). Research by the Electronic Cigarette Quality Organisation reckons on an average of nine puffs per cigarette, compared with 300 puffs per ml of liquid nicotine. When you crunch the numbers, smoking e-cigarettes can work out at 6p for an equivalent normal cigarette.

The cheapest packet of 20 cigarettes works out at 30p a cigarette, or over 40p for premium brands. Someone smoking 20 a day could save £1,750 per year. You can see why some people are worried for the tobacco companies.

But it might not be that simple. From 2016 e-cigarettes will be regulated as a medicine. Will the small companies selling them be able to cope with the burden and costs of this?

The big tobacco companies have been dealing with regulation for ages and are well placed to cope with it.

They are also developing their own e-cigarettes. BATS has launched one called Vype, but it’s difficult to work out whether this will make as much money as normal cigarettes over the long run.

Is there profit in the pipeline?

It’s probably fair to say that BATS’s days of stellar profit growth are behind it, while lots of challenges still remain for the company. The EU is going after its crown jewels of premium cigarettes and is banning flavoured products from 2022.

Taxes on tobacco will keep on going up, which will increase competition from illegal sources. More countries will look to introduce smoking bans in public places.

While there’s lots of uncertainty, it’s easy to overlook the fact that BATS still has a lot of things going for it. Its strategy of focusing on four premium brands (ones with flavours, or slimmer cigarettes) continues to keep profits growing.

Despite demand for cigarettes falling, tobacco companies retain their tremendous ability to keep on raising prices without too many people switching brands. That’s because for years they have been increasing prices at the same time as the government increases taxes, so customers don’t really see the full extent of the company’s actions.

This keeps profit margins high for now. In fact, BATS remains one of the most profitable businesses out there. Profit margins were 37.4% in 2012 and are still increasing. Return on capital employed (ROCE) is an impressive 30%. The company doesn’t have too much debt and is very good at turning profits into surplus cash in order to pay higher dividends.

Should you buy the shares

This means that the company and its shares should not be written off just yet. In fact, BATS still has all the hallmarks of a quality income stock. These types of shares have seen their prices bid up to very high levels, with many of them now looking quite expensive.

The fact that there are worries about the future means that BATS’s shares have missed out on this rally.

This left the shares looking a bit cheap on just over 13 times this year’s expected profits. BATS is expected to announce a dividend increase of 6% for 2013 at the end of next month, with analysts expecting another 5% increase for 2014.

This puts the shares on a prospective dividend yield of nearly 5%, which is not too shabby. After that, I think that a dividend cut is unlikely for the foreseeable future and that dividends can probably still increase in line with inflation for a good while yet.

Verdict: buy for income

British American Tobacco (LSE: BATS)

BAT share price chartShare price: 3,066p
Market cap: £57.3bn
Net assets (June 2013): £7bn
Net debt (June 2013): £10.5bn
P/e (prospective): 13.3 times
Yield (prospective): 4.9%
Dividend cover: 1.5 times
Interest cover: 11.2 times

BAT earnings per share chartWhat the analysts say

Buy: 17
Hold: 10
Sell: 2
Target price: 3,708p

Directors’ shareholdings

N Durante (CEO): 160,418
B Stevens (CFO): 121,200
R Burrows (chair): 10,000